Rosen Amends Arcus Biosciences Stake Filing

TL;DR

Terry Rosen updated his Arcus Biosciences (RCUS) 13D filing. Details on ownership change TBD.

AI Summary

Terry J. Rosen, through an amendment filed on December 17, 2024, has updated his Schedule 13D filing for Arcus Biosciences, Inc. The filing indicates a change in the beneficial ownership of Arcus Biosciences' common stock. The specific details of the change in ownership percentage or number of shares are not fully detailed in the provided excerpt, but it represents an amendment to a previous filing.

Why It Matters

This filing provides insight into significant changes in beneficial ownership for Arcus Biosciences, potentially signaling shifts in investor sentiment or strategy.

Risk Assessment

Risk Level: medium — Schedule 13D filings often indicate significant stake changes by major holders, which can impact stock price and corporate strategy.

Key Players & Entities

• Arcus Biosciences, Inc. (company) — Subject Company
• Terry J. Rosen (person) — Filing Person
• ROSEN TERRY J (person) — Filing Person

FAQ

Key Financial Figures

• $0.0001 — me of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 0396

Filing Documents

• d902840dsc13da.htm (SC 13D/A) — 31KB
• 0001193125-24-280681.txt ( ) — 32KB

of the Schedule 13D is hereby amended and restated in its entirety as follows

Item 2 of the Schedule 13D is hereby amended and restated in its entirety as follows: (a) Names: (1) Terry Rosen, Ph.D. (b) Residence or Business Address of Reporting Persons: Arcus Biosciences, Inc. 3928 Point Eden Way Hayward, CA 94545 (c) Terry Rosen, Ph.D. is the Chief Executive Office and a director of the Issuer. (d) During the last five years, the Reporting Person has not been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors). (e) During the last five years, the Reporting Person has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. (f) Citizenship: Terry Rosen, Ph.D. - United States Item5. Interest in Securities of the Issuer

of the Schedule 13D is hereby amended and restated as follows

Item 5 of the Schedule 13D is hereby amended and restated as follows: (a)-(b) As of December 16, 2024, Dr. Rosen beneficially owns 3,790,875 shares of Common Stock. This amount represents 4.10% of the Issuers outstanding Common Stock as of October 30, 2024 and includes 2,226,479 shares of Common Stock held directly by Dr. Rosen, 931,422 shares of Common Stock underlying options exercisable within sixty days of December 16, 2024 and 632,974 held in various trusts for which Dr. Rosen serves as the trustee. Dr. Rosen holds sole voting and investment power over these shares. (c) On October 28, 2024, Dr. Rosen entered into a divorce settlement agreement with his ex-spouse (the Settlement Agreement) pursuant to which Dr. Rosen transferred 1,541,661 shares of Common Stock, 5,401 Restricted Stock Units and options to purchase 443,926 shares of Common Stock to his ex-spouse. (d) Not applicable. (e) This Amendment No. 1 is being filed to report that, as of the date hereof, Dr. Rosen no longer beneficially owns more than five percent of the Common Stock. CUSIP No. 03969F109

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: December 17, 2024 By: /s/ Terry Rosen Terry Rosen, Ph.D.

View Full Filing

View this SC 13D/A filing on SEC EDGAR